8-K: Geron Reports Q1 2025 Financial Results: RYTELO Revenue at $39.4 Million, EU Approval Granted

Geron Corporation announced its first quarter 2025 financial results, highlighted by $39.4 million in RYTELO net product revenue and European Commission approval for RYTELO.

Summary

• Geron Corporation reported first quarter 2025 financial results on May 7, 2025.
• RYTELO net product revenue was $39.4 million in Q1 2025, impacted by inventory dynamics.
• Demand for RYTELO increased 1% in the 13-week period ending March 28 compared to the prior 13 weeks.
• The European Commission granted marketing authorization for RYTELO, with commercial launch in select EU countries planned for 2026.
• Enrollment in the Phase 3 IMpactMF clinical trial reached approximately 85%, with interim analysis expected in the second half of 2026.
• Geron's net loss for Q1 2025 was $19.8 million, or $0.03 per share, compared to a net loss of $55.4 million, or $0.09 per share, for the same period in 2024.
• As of March 31, 2025, Geron had approximately $457.5 million in cash, cash equivalents, restricted cash, and marketable securities.
• Total operating expenses for 2025 are expected to be between $270 million and $285 million.
• The company believes existing cash, cash equivalents, and marketable securities, along with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, revenue from RYTELO is growing, and the European approval is a significant positive. However, the revenue decline compared to the previous quarter and increased operating expenses temper the overall outlook.

Positives

• RYTELO achieved $39.4 million in net product revenue in its first year of U.S. commercialization.
• The European Commission approved RYTELO, expanding its market reach.
• Enrollment in the Phase 3 IMpactMF trial is progressing well, reaching 85% completion.
• The net loss decreased significantly compared to the same period in the previous year (from $55.4 million to $19.8 million).
• The company maintains its financial guidance for 2025 operating expenses.
• Geron believes its current financial resources are sufficient to fund operations for the foreseeable future.

Negatives

• RYTELO revenue declined compared to the previous quarter due to inventory drawdown among distributors.
• The company reported a net loss of $19.8 million for the quarter.
• Selling, general, and administrative expenses increased due to commercialization efforts for RYTELO.

Risks

• Commercial success of RYTELO depends on market acceptance and achieving broad prescriber uptake.
• Regulatory approval for imetelstat in other indications is not guaranteed.
• The IMpactMF trial's success and timeline are subject to enrollment rates and patient event occurrences.
• Manufacturing or supply chain issues could impact RYTELO commercialization and clinical trials.
• The company's financial projections depend on continued U.S. sales of RYTELO.

Future Outlook

Geron expects to commercialize RYTELO in select EU countries in 2026 and anticipates an interim analysis of the Phase 3 IMpactMF trial in the second half of 2026. The company believes its current financial resources, along with U.S. sales of RYTELO, will be sufficient to fund operations for the foreseeable future.

Management Comments

• Dawn Carter Bir, Interim President and Chief Executive Officer of Geron, stated that they are confident in the long-term potential of RYTELO and are focused on maximizing the U.S. commercial opportunity.
• Management believes increased commercial investments will bolster uptake across a broader group of prescribers and drive long-term demand.

Industry Context

Geron's focus on RYTELO and imetelstat positions it within the competitive landscape of biopharmaceutical companies developing treatments for blood cancers, specifically myelodysplastic syndromes and myelofibrosis. The European Commission approval of RYTELO expands Geron's market reach and potential revenue streams.

Comparison to Industry Standards

• Geron's RYTELO competes with other therapies for lower-risk MDS, such as erythropoiesis-stimulating agents (ESAs) and other novel treatments.
• The IMpactMF trial aims to address the unmet need for effective treatments in JAK inhibitor-relapsed/refractory myelofibrosis, where options are limited.
• Companies like Incyte (Jakafi) and Bristol Myers Squibb (Reblozyl) are key players in the myelofibrosis and MDS markets, respectively.
• Geron's $39.4 million in RYTELO revenue is a key metric to watch compared to the sales performance of competing drugs in similar indications.

Stakeholder Impact

• Shareholders: The financial results and business updates provide insights into the company's performance and future prospects.
• Employees: The company's commercialization and clinical trial efforts impact employee roles and responsibilities.
• Patients: RYTELO's availability and potential approval in new indications affect treatment options for patients with MDS and myelofibrosis.
• Clinicians: Increased awareness and education about RYTELO can influence prescribing practices.
• Creditors: The company's financial stability and ability to meet its obligations are relevant to creditors.

Next Steps

• Continue U.S. commercialization of RYTELO.
• Plan for commercial launch of RYTELO in select EU countries in 2026.
• Advance the Phase 3 IMpactMF clinical trial and prepare for the interim analysis in the second half of 2026.
• Expand medical affairs efforts to support increased awareness and education about RYTELO.

Key Dates

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, myelofibrosis, Geron, financial results, commercialization, clinical trial, IMpactMF, European Commission